Pediatric Myopia Treatment Study
Multicenter study of the Safety and Efficacy of OT-101 (Atropine Sulfate 0.01%) in Treating the Progression of Myopia in Pediatric Subjects
SEX AT BIRTH: All
CONDITION: Myopia, Progressive
LOCATION: University Hospitals Cleveland Medical Center
The purpose of this research study is to determine if the investigational eye drop OT-101 can treat the progression of myopia.
Who Can Participate
Participants between 3 and 15 years old diagnosed with myopia may be eligible for this study.
- STUDY ID# 20210309